Catalyst Pharmaceutical Partners Price Target Increased to $5.50 by Analysts at Aegis (CPRX)
Research analysts at Aegis raised their price objective on shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) from $4.00 to $5.50 in a report released on Monday, AnalystRatings.Net reports. The firm currently has a “buy” rating on the stock. Aegis’ target price indicates a potential upside of 189.47% from the company’s current price.
Shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) opened at 1.85 on Monday. Catalyst Pharmaceutical Partners has a 1-year low of $0.37 and a 1-year high of $3.65. The stock’s 50-day moving average is $2.69 and its 200-day moving average is $1.40. The company’s market cap is $76.7 million.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) last posted its quarterly earnings results on Thursday, August 15th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.07) by $0.01. On average, analysts predict that Catalyst Pharmaceutical Partners will post $-0.24 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on CPRX. Analysts at Zacks upgraded shares of Catalyst Pharmaceutical Partners from a “neutral” rating to an “outperform” rating in a research note to investors on Friday. They now have a $3.10 price target on the stock. Finally, analysts at Roth Capital raised their price target on shares of Catalyst Pharmaceutical Partners from $2.75 to $3.75 in a research note to investors on Wednesday, October 16th.
Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of addiction and epilepsy.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.